Keio University Publishes Long-Term Safety Data in Nature Medicine for iPSC-Derived Neural Stem Cell Transplant in Spinal Cord Injury: No Tumor Formation or Serious Adverse Events Over Four Years

August 17, 2026

OmniGenix Japan

Overview

A research team at Keio University has published groundbreaking long-term safety data in Nature Medicine from the world’s first clinical study of iPSC-derived neural stem cell transplantation for spinal cord injury, demonstrating no tumor formation or serious adverse events over up to four years. This pivotal study marks a critical milestone in evaluating the long-term safety of iPSC-based therapies. The findings strongly support the promise of iPSCs as a viable option for nerve injury treatment.

In Depth

Key Findings

A research team from Keio University has published groundbreaking long-term safety data in Nature Medicine, derived from the world’s first clinical study on spinal cord injury treatment using induced pluripotent stem cell (iPSC)-derived neural stem cells. The study confirmed that over a follow-up period of up to four years, no tumor formation or other serious adverse events attributed to the transplanted cells were reported. This represents a critically important achievement, validating that iPSC-based regenerative medicine has cleared the paramount hurdle of safety and holds significant promise as a therapeutic option for nerve injuries.

Technical / Clinical Details

This clinical study involved the direct transplantation of neural stem cells, differentiated from iPSCs, into the injury site of spinal cord injury patients. The transplanted neural stem cells are expected to differentiate into neurons and glial cells at the injury site, promoting the reconstruction of neural circuits, neuroprotective effects, and anti-inflammatory benefits, thereby facilitating the recovery of motor and sensory functions. The primary focus of this recent publication was not just on therapeutic efficacy, but specifically on long-term safety. One of the main concerns with iPSC-derived cell therapies has been the risk of tumor formation if undifferentiated iPSCs persist. Keio University’s study, through rigorous cell selection and differentiation protocols, demonstrated that this risk can be effectively managed, as evidenced by four years of long-term data. This significantly enhances confidence in the safety of iPSC-derived cell therapies for clinical application.

Background & Context

Spinal cord injury is an intractable condition that causes severe motor dysfunction and sensory paralysis, significantly diminishing patients’ quality of life. Conventional treatments have largely failed to regenerate damaged neural tissue, offering little hope for fundamental recovery. Since the discovery of iPSCs, regenerative medicine has emerged as a new hope for spinal cord injury treatment, but the safety of cell transplantation, particularly the risk of tumor formation, has always been a subject of intense debate. Keio University’s long-term safety data represent a major breakthrough in this field, indicating that iPSC-based neural regenerative medicine is making significant strides towards practical application. This achievement is expected to profoundly influence neural regenerative medicine research worldwide and accelerate iPSC application studies for other neurodegenerative diseases.

Strategic Significance & Outlook

The publication of this long-term safety data substantially increases the likelihood that iPSC-derived neural stem cell transplantation could become a standard treatment for spinal cord injury. Future efforts will require large-scale clinical trials involving more patients to confirm efficacy data and establish a more detailed safety profile. Furthermore, investigating the synergistic effects with post-transplant rehabilitation and expanding indications to patients with more severe injuries will be crucial research areas. Keio University’s achievement not only enhances the credibility of iPSC technology and contributes to the overall development of neural regenerative medicine but is also expected to serve as a model case for long-term safety evaluations in iPSC application studies for other organ and tissue injuries. This brings the future of widely available iPSC-based regenerative medicine a significant step closer.

Source: https://omnigenix.com/stem-cell-therapy-spinal-cord-injury-2026-research-update/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.